Steve Lenier

Steve Lenier

Contributing Writer

Steve Lenier began a career in medical literature over 30 years ago. He has worked on a variety of publications and projects, and across a number of specialties. Since 2005 most of his time has been spent covering ophthalmology, both print and online.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma

February 16 2021

Verana Health and Janssen Enter Real-World Data and Data Science Collaboration

Verana Health has entered into a research collaboration with Janssen Research & Development, a unit of Johnson & Johnson, that focuses on curating real-world data ...
Read More

January 5 2021

Looking Ahead to 2021, Finding Value in 2020’s Lessons

Robert Kissling, VP, medical affairs for Bausch + Lomb, says forced changes can be the mother of innovation. If so, then 2020 should have sired ...
Read More

December 1 2020

Awareness and Innovation May Address Underdiagnosed Dry Eye Population

Dry eye disease is notoriously underdiagnosed. It’s also a market with a strong upside potential. In a recent interview with OIS Weekly, internationally known anterior ...
Read More

November 24 2020

Reimbursement Will Guide Innovation in Glaucoma

In ophthalmic innovation, great ideas only go so far. Without a potential revenue stream, investors would leave great ideas at the bench. In glaucoma, however, ...
Read More

November 10 2020

Exploring Why Pharma Hesitates to Embrace Drug-Delivery Methodologies

Drug-delivery technologies typically aim to improve pharmacologic and therapeutic properties of already approved drugs, but pharmaceutical companies are sometimes hesitant to acquire, develop, or invest ...
Read More

October 28 2020

The Next Wave of Glaucoma Innovation: Moving Beyond MIGS

Part 2 of 2 Micro-invasive glaucoma surgery (MIGS) has been in the forefront of innovation in the glaucoma space, and while MIGS innovation still has ...
Read More

October 20 2020

COVID Can’t Lock Down Innovation in Glaucoma

Part 1 of 2 The global COVID-19 pandemic has caused some changes in how companies in the glaucoma space pursue new products and technology, but ...
Read More

October 14 2020

Ocular Therapeutix Makes Lots of Buzz. Wall Street Notices

Reporting positive top-line clinical trial results, initiating two other clinical trials, getting wider Medicare coverage of its lead product, resolving a regulatory warning letter, and ...
Read More

August 26 2020

Underserved Dry Eye Populations Offer Opportunity for Developing Technologies

The population of US dry eye patients is greatly underserved, but innovative treatments in development are poised to provide more treatment options and capture at ...
Read More

August 12 2020

Bausch Health Spin-Off of Eye Care Business Follows a Familiar Playbook

As Bausch Health pursues a spin-off of its eye health business into an independent company, it’s following a playbook that’s scored well in ophthalmology, and ...
Read More
OIS Virtual Public Company Showcase Panel

July 22 2020

‘A Very Interesting Time’ and Other Insights from OIS Virtual Public Company Showcase

In this time of virtual meetings, the Ophthalmology Innovation Summit (OIS) continues to deliver information and foster innovation. Last week’s OIS Virtual Public Company Showcase ...
Read More
AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

July 9 2020

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

Weeks after completing its acquisition of Allergan, AbbVie is seeking a meeting with the US Food and Drug Administration to talk about the next steps ...
Read More